



Letter to the Editor

A Potential Mechanism for Lactoferrin to Prevent and Inhibit Organ Fibrosis



Mengqin Guo^{1#}, Yang Liu^{2#}, Jiezuan Cen^{1#}, Chuanbin Wu¹ and Zhengwei Huang^{1*}

¹State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, China; ²School of Pharmacy, Chongqing Medical and Pharmaceutical College, Chongqing, China

Received: June 03, 2025 | Revised: June 24, 2025 | Accepted: July 31, 2025 | Published online: August 21, 2025

Dear Editors,

Numerous reviews, including the one authored by Yu *et al.*,¹ have synthesized evidence regarding the fibrosis-preventing activity of lactoferrin. The classical mechanisms through which lactoferrin prevents organ fibrosis encompass the inhibition of inflammatory responses, modulation of oxidative stress, and remodeling of the extracellular matrix. In contrast, emerging mechanisms involve the regulation of microbiota abundance and potential microRNA targeting. Additionally, lactoferrin affects the progression of organ fibrosis by modulating autophagy, mitochondrial function, and senescence (Fig. 1).² It is noteworthy that these integrative reviews were supported by original studies, thus lending credibility to the extracted conclusions. Overall, the current body of knowledge offers a valuable integration of the interplay between lactoferrin and organ fibrosis, providing important guidance for future research in this field.

This letter aims to propose potential refinements to the emerging mechanisms of lactoferrin in preventing organ fibrosis, which may enhance the value of the previously mentioned mechanisms. Specifically, we suggest that lactoferrin's ability to inhibit ferroptosis may contribute to its organ fibrosis-preventing properties. We will briefly clarify this assertion through a syllogistic approach,³ a classic logical tool that has been employed for centuries. For clarity, we provide a simple example to demonstrate the logical progression in a syllogistic manner.

Example:

- Statement 1 (major premise): Protein molecules contain amide bonds (-NH-CO-).
- Statement 2 (minor premise): Lactoferrin is a protein.
- Statement 3 (inference): Lactoferrin molecules contain amide bonds.

This example illustrates how robust inferences can be drawn

from existing knowledge. Following this logical structure, we propose the exploration of previously unconsidered mechanisms by which lactoferrin might prevent organ fibrosis. The detailed syllogistic analysis is outlined below:

Statement 1 (major premise): Ferroptosis inhibition alleviates organ fibrosis. Ferroptosis has been extensively implicated in the pathological processes of organ fibrosis.⁴ Our focus, within the context of respiratory pharmacology, is on the relationship between ferroptosis and pulmonary fibrosis. The transferrin receptor (TFRC) in lung fibroblasts is upregulated, leading to iron accumulation.⁵ The resulting elevated iron deposition,⁶ coupled with the suppression of glutathione peroxidases 4 (GPX4) and ferroptosis suppressor protein-1,⁷ induces ferroptosis in normal pulmonary cells, contributing to the pathogenesis of pulmonary fibrosis. In other words, ferroptosis induction promotes pulmonary fibrosis progression. Conversely, inhibiting ferroptosis can impede the advancement of pulmonary fibrosis, suggesting it as a potential therapeutic target.⁸

Statement 2 (minor premise): Lactoferrin is an inhibitor of ferroptosis. Previous studies have documented at least three mecha-




Fig. 1. Potential mechanisms through which lactoferrin affects organ fibrosis. miRNA, microRNA.

*Correspondence to: Zhengwei Huang, State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong 511436, China. ORCID: <https://orcid.org/0000-0003-2351-7347>. Tel: +86-020-39943117, E-mail: huangzhengw@jnu.edu.cn

[#]These authors contributed equally to this work.

How to cite this article: Guo M, Liu Y, Cen J, Wu C, Huang Z. A Potential Mechanism for Lactoferrin to Prevent and Inhibit Organ Fibrosis. *J Explor Res Pharmacol* 2025;10(3):e00028. doi: 10.14218/JERP.2025.00028.




Fig. 2. Logical flow of the syllogistic argument.

nisms through which lactoferrin inhibits ferroptosis: iron chelation,⁹ upregulation of GPX4,¹⁰ and inhibition of the acyl-CoA synthetase long-chain family member 4 (ACSL4)/TFRC-1/nuclear receptor coactivator 4 pathway.¹¹ Iron chelation, upregulation of GPX4, and inhibition of ACSL4/TFRC-1/nuclear receptor coactivator 4 will suppress ferroptosis-inducing factors while promoting ferroptosis-inhibiting factors. These mechanisms may act synergistically to inactivate the ferroptosis pathway in fibrosis-related cells. Specifically, the molecular mechanisms by which lactoferrin intervenes in the three core pathways of ferroptosis are iron homeostasis regulation (TFRC/ferritin pathway), lipid peroxidation defense (GPX4/glutathione axis), and maintenance of cell membrane integrity (ACSL4-mediated polyunsaturated fatty acid metabolism). Additionally, lactoferrin can target the ferroptosis pathway through iron chelation and antioxidant synergy activated by GPX4, thereby achieving an innovative therapeutic paradigm of “multi-targeted intervention in ferroptosis in fibrosis-related cells.”

Statement 3 (inference): Lactoferrin, through ferroptosis inhibition, can prevent organ fibrosis. This inference logically follows from the previous two premises, as demonstrated in the syllogistic example. Although this hypothesis reveals a new dimension of lactoferrin’s anti-fibrotic action, the causal relationship of this hypothesis still needs to be further verified through targeted experiments (such as gene knockout or pathway inhibitors).

The logical flow of this reasoning is concisely illustrated in Figure 2.

Based on the above deduction, we infer that lactoferrin’s ferroptosis-inhibitory capacity may provide an alternative pathway for preventing organ fibrosis. The potential targets for lactoferrin might include: TFRC/ferritin pathway, GPX4/glutathione axis, and ACSL4-mediated polyunsaturated fatty acid metabolism. As this mechanism has not been widely discussed, it offers a fresh perspective. Although we present this theory logically through syllogism, we recommend that researchers in this field further investigate the ferroptosis-related mechanisms of lactoferrin and gather solid evidence. Both *in vitro* and *in vivo* studies are anticipated to provide valuable insights. We are optimistic that, with continued investigation, lactoferrin-based therapeutic strategies for organ fi-

bro sis treatment will be developed in the near future.

In conclusion, this letter proposes a compelling mechanism by which lactoferrin may prevent organ fibrosis, contributing to a better understanding of the mechanisms underlying lactoferrin-targeted therapies.

Acknowledgments

None.

Funding

This research was supported by Special Funding of Fundamental Research Funds for the Central Universities (grant No. 21625412).

Conflict of interest

The authors declare no conflicts of interest.

Author contributions

Formal analysis, manuscript writing (MG), investigation (YL, JC), supervision, proof-reading (CW), writing-review & editing, conceptualization, and funding acquisition (ZH). All authors have approved the final version and publication of the manuscript.

References

- [1] Yu Y, Fang J, Li Y, Wang X, Zhang J, Wang J, *et al*. The Novel Effect and Potential Mechanism of Lactoferrin on Organ Fibrosis Prevention. *Nutrients* 2025;17(1):197. doi:10.3390/nu17010197, PMID:39796631.
- [2] Hsu YH, Chiu IJ, Lin YF, Chen YJ, Lee YH, Chiu HW. Lactoferrin Contributes a Renoprotective Effect in Acute Kidney Injury and Early Renal Fibrosis. *Pharmaceutics* 2020;12(5):434. doi:10.3390/pharmaceutics12050434, PMID:32397266.
- [3] Karavia A, Papaioannou A, Michopoulos I, Papageorgiou PC, Papaioannou G, Gonidakis F, *et al*. Using Electroencephalogram-Extracted

- Nonlinear Complexity and Wavelet-Extracted Power Rhythm Features during the Performance of Demanding Cognitive Tasks (Aristotle's Syllogisms) in Optimally Classifying Patients with Anorexia Nervosa. *Brain Sci* 2024;14(3):251. doi:10.3390/brainsci14030251, PMID:38539639.
- [4] Huang X, Song Y, Wei L, Guo J, Xu W, Li M. The emerging roles of ferroptosis in organ fibrosis and its potential therapeutic effect. *Int Immunopharmacol* 2023;116:109812. doi:10.1016/j.intimp.2023.109812, PMID:36746022.
- [5] Pei Z, Qin Y, Fu X, Yang F, Huo F, Liang X, *et al*. Inhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model. *Redox Biol* 2022;57:102509. doi:10.1016/j.redox.2022.102509, PMID:36302319.
- [6] Cheng H, Feng D, Li X, Gao L, Tang S, Liu W, *et al*. Iron deposition-induced ferroptosis in alveolar type II cells promotes the development of pulmonary fibrosis. *Biochim Biophys Acta Mol Basis Dis* 2021;1867(12):166204. doi:10.1016/j.bbadis.2021.166204, PMID:34175430.
- [7] Liu Y, Cheng D, Wang Y, Xi S, Wang T, Sun W, *et al*. UHRF1-mediated ferroptosis promotes pulmonary fibrosis via epigenetic repression of GPX4 and FSP1 genes. *Cell Death Dis* 2022;13(12):1070. doi:10.1038/s41419-022-05515-z, PMID:36566325.
- [8] Guo M, Peng T, Wu C, Pan X, Huang Z. Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis. *Bioengineering (Basel)* 2023;10(6):727. doi:10.3390/bioengineering10060727, PMID:37370658.
- [9] Xiao Z, Shen D, Lan T, Wei C, Wu W, Sun Q, *et al*. Reduction of lactoferrin aggravates neuronal ferroptosis after intracerebral hemorrhagic stroke in hyperglycemic mice. *Redox Biol* 2022;50:102256. doi:10.1016/j.redox.2022.102256, PMID:35131600.
- [10] Fan YG, Ge RL, Ren H, Jia RJ, Wu TY, Lei XF, *et al*. Astrocyte-derived lactoferrin inhibits neuronal ferroptosis by reducing iron content and GPX4 degradation in APP/PS1 transgenic mice. *Pharmacol Res* 2024;209:107404. doi:10.1016/j.phrs.2024.107404, PMID:39306020.
- [11] Salama RM, Darwish SF, Yehia R, Sallam AA, Elmongy NF, Abd-Elgalil MM, *et al*. Lactoferrin alleviates gentamicin-induced acute kidney injury in rats by suppressing ferroptosis: Highlight on ACSL4, SLC7A11, NCOA4, FSP1 pathways and miR-378a-3p, LINC00618 expression. *Food Chem Toxicol* 2024;193:115027. doi:10.1016/j.fct.2024.115027, PMID:39357596.